



Division: Pharmacy Policy	Subject: Prior Authorization Criteria
Original Development Date:	October 15, 2015

## **CHEMET<sup>®</sup> (succimer)**

**LENGTH OF AUTHORIZATION:** Up to 19 days

**CLINICAL NOTES:** Succimer is an orphan drug used in the treatment of lead poisoning in children whose blood lead concentrations are > 45 mcg/dL. Identification and removal of the source of lead exposure should be accompanied with treatment.

**REVIEW CRITERIA:**

- Patient must be  $\geq 12$  months of age
- Patient must be diagnosed with lead poisoning by a toxicologist/ specialist with chelating agents (or in consultation with)
- Blood levels above 45 mcg/dL for children (<18) and above 70mcg/dL for adults (18 and older) (supporting labs must be submitted with request)

**CONTINUATION OF THERAPY:**

- Clinical rationale from the prescriber for continued therapy
- Blood levels above 45 mcg/dL (supporting labs must be submitted with request)

**DOSING & ADMINISTRATION:**

**Children** ( $\geq 12$  months-< 18 years of age):

**10 mg/kg every 8 hours for 5 days, then 10 mg/kg every 12 hours for 14 days**

**Adult patients** ( $\geq 18$  years of age or older) **10 to 30 mg/kg/day for 5 days**